Karyopharm Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Karyopharm Therapeutics

02/11/2023 13:33

* Karyopharm Therapeutics Inc  KPTI.OQ  reported a quarterly
adjusted loss of 30 cents​​ per share for the quarter ended in
September, higher than the same quarter last year, when the
company reported EPS of -45 cents.  The mean expectation of
ten analysts for the quarter was for a loss of 28 cents per
share. Wall Street expected results to range from -32 cents
to -23 cents per share.
    * Revenue fell 0.4% to $36.01 million from a year ago;
analysts
expected $37.28 million. 
    * Karyopharm Therapeutics Inc's reported EPS for the quarter
was a
loss of 30 cents​.
    * The company reported a quarterly loss of $34.51 million.
    * Karyopharm Therapeutics Inc shares had fallen by 41.3%
this
quarter and lost 76.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Karyopharm
Therapeutics Inc is $6.00 
This summary was machine generated from LSEG data November 2 at
01:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.28          -0.30          Missed
 Jun. 30 2023      -0.34          -0.29          Beat
 Mar. 31 2023      -0.37          -0.30          Beat
 Dec. 31 2022      -0.35          -0.43          Missed